0.366
price down icon6.15%   -0.024
after-market 시간 외 거래: .37 0.004 +1.09%
loading
전일 마감가:
$0.39
열려 있는:
$0.39
하루 거래량:
157.92K
Relative Volume:
1.62
시가총액:
$13.07M
수익:
$45.91M
순이익/손실:
$-4.62M
주가수익비율:
-2.6106
EPS:
-0.1402
순현금흐름:
$-21.51M
1주 성능:
-9.85%
1개월 성능:
-12.86%
6개월 성능:
-48.47%
1년 성능:
-75.60%
1일 변동 폭
Value
$0.35
$0.393
1주일 범위
Value
$0.346
$0.401
52주 변동 폭
Value
$0.3442
$1.51

Equillium Inc Stock (EQ) Company Profile

Name
명칭
Equillium Inc
Name
전화
(858) 412-5302
Name
주소
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
직원
35
Name
트위터
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
EQ's Discussions on Twitter

EQ을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
EQ
Equillium Inc
0.366 14.29M 45.91M -4.62M -21.51M -0.1402
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Equillium Inc Stock (EQ) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-28 다운그레이드 Leerink Partners Outperform → Market Perform
2021-10-29 재개 Stifel Buy
2021-09-15 개시 Cantor Fitzgerald Overweight
2020-07-14 재확인 H.C. Wainwright Buy
2020-07-10 재개 Stifel Buy
2019-02-22 개시 SVB Leerink Outperform
모두보기

Equillium Inc 주식(EQ)의 최신 뉴스

pulisher
May 22, 2025

Equillium expands equity incentive plan by 1.78 million shares - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Equillium Holds Annual Stockholders Meeting on Key Proposals - TipRanks

May 22, 2025
pulisher
May 07, 2025

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - BioSpace

May 07, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Sells 59,773 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World

May 07, 2025
pulisher
May 05, 2025

Equillium stock touches 52-week low at $0.52 amid market challenges - MSN

May 05, 2025
pulisher
May 04, 2025

Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World

May 04, 2025
pulisher
May 01, 2025

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - BioSpace

May 01, 2025
pulisher
Apr 25, 2025

FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter

Apr 25, 2025
pulisher
Apr 24, 2025

Equillium shares fall following FDA feedback By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium shares fall following FDA feedback - Investing.com Australia

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

FDA declines Equillium’s itolizumab accelerated approval - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire

Apr 24, 2025
pulisher
Apr 22, 2025

Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World

Apr 22, 2025
pulisher
Apr 01, 2025

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter

Mar 30, 2025
pulisher
Mar 30, 2025

Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

Equillium Reports 2024 Financials and Clinical Milestones - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan

Mar 27, 2025

Equillium Inc (EQ) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
자본화:     |  볼륨(24시간):